Treatment of Viral Encephalitis in Epstein-Barr Virus (EBV) Infection

Encephalitis arising in the setting of Epstein-Barr virus infection is a distinct clinical presentation that requires a specific management approach. The treatment strategy differs meaningfully from other viral encephalitides.

Clinical Scenario

Epstein-Barr virus encephalitis, including neurological complications of EBV infection such as encephalomyelitis. Standard antiviral agents used in other forms of viral encephalitis are not recommended for this presentation.

Treatment Approach

The approach involves a class of anti-inflammatory agents that may provide benefit in selected patients — the full structured regimen, including when and how to weigh the relevant risks, is in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1086/589747

Epstein-Barr virus: acyclovir is not recommended; the use of corticosteroids may be beneficial (C-III), but the potential risks must be weighed against the benefits.

Corticosteroids were reported to be helpful in several anecdotal reports of neurologic complications of infection with Epstein-Barr virus (including encephalomyelitis) and have been used in patients with increased intracranial pressure; these data suggest that they may be beneficial in selected patients, but their potential benefits must be weighed against potential risk of perpetuating viral infection or of delaying the diagnosis of or partially treating AIDS-related CNS lymphoma.

View source ↗